Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The brain’s networks activate in structured cycles, according to a major new study led by the Department of Psychiatry at the University of Oxford.

A graphical image of a brain with liens representing connections © Shutterstock

The human brain flexibly fulfils numerous cognitive roles that are essential for survival, such as memory, attention and sensory processing. However, little is known about the organisational framework that ensures that these functions get carried out within specific timeframes.

The team analysed five large magnetoencephalography (MEG) datasets, with brain activity recordings from more than 800 people, to study the activity of large cortical brain networks. They found that although networks do not activate in a strict order, they do tend to activate in a characteristic pattern that repeats cyclically every 300–1,000 milliseconds.

The strength and speed of the cycles identified were found to be influenced by genetics, and closely associated with several factors. For example, faster reaction times are associated with stronger cycles, with fewer deviations from the characteristic pattern, demonstrating their relevance for cognitive performance; and older individuals exhibit slower cycles, aligning with observations of age-related cognitive slowing.

The study was published in the journal Nature Neuroscience and conducted at the University of Oxford’s Department of Psychiatry, in collaboration with the University of Birmingham, Aarhus University in Denmark, and industry partner Resonait Medical Technologies. It was supported by the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre (BRC).

 

Read the full story on the Department of Psychiatry website. 

 

 

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.